A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Summary

The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Chickenpox

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 to 15 months

Sex

All

Healthy volunteers

Accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

May 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites